###### Strengths and limitations of this study

-   This study uses a randomised crossover design to investigate, for the first time, cardiovascular disease risk marker responses to breaking up prolonged sedentary time in individuals with paraplegia.

-   Regular collection of blood samples will permit robust time course and incremental area under the curve calculations for primary and secondary outcomes.

-   Due to the acute nature of the study, the long-term cardiovascular disease risk marker responses to a chronic intervention will remain unknown.

-   The cardiovascular disease risk marker responses to breaking up prolonged sedentary time in people with tetraplegia still requires investigation.

Introduction {#s1}
============

There is a global incident rate of 180 000 traumatic spinal cord injury (SCI) cases each year with a prevalence of over 40 000 in the UK.[@R1] Cardiovascular disease (CVD) is a leading cause of death in individuals with SCI,[@R3] and this population has a significantly increased risk of heart disease and stroke compared with able-bodied individuals.[@R4] Traditional risk factors for CVD include impaired glucose tolerance, central obesity, high triglycerides, low high-density lipoprotein cholesterol (HDL) and high blood pressure. These risk factors often exacerbate significantly as a consequence of SCI,[@R5] and a plethora of research has documented impaired glucose tolerance and adverse lipid profiles in individuals with SCI.[@R5] The clustering of ≥2 and ≥3 risk factors is prevalent in 87% and 72% of SCI individuals, respectively,[@R7] which is markedly higher compared with the able-bodied population.[@R8] This milieu of metabolic disturbances after SCI may be due to increases in body fat resulting from an imbalance in energy intake and expenditure.[@R5] Excess fat accumulation, particularly in the visceral region, is associated with inflammation that is causal in glucose intolerance and dyslipidaemia,[@R5] thus promoting atherogenesis that would increase the risk of CVD in this population.[@R10]

Postprandial glucose and lipid concentrations are strong independent predictors of future CVD incidence, even in those without diabetes.[@R11] There is a dose--response relationship between postprandial glucose area under the curve (AUC) and CVD risk, while progression of carotid atherosclerosis can be prevented by attenuation of postprandial glucose concentrations.[@R12] Impaired postprandial glucose metabolism was observed in 50% and 62% of individuals with paraplegia and tetraplegia, respectively, compared with 18% in able-bodied individuals.[@R6] This impaired glucose tolerance in SCI is characterised by hyperinsulinaemia, which suggests that there is tissue-level resistance to insulin.[@R14] In individuals with paraplegia, there appears to be no difference in postprandial glucose responses between those with complete versus incomplete lesions.[@R15] Although postprandial lipaemic responses have not been compared between individuals with complete and incomplete lesions, fasting lipid levels do not differ between these groups.[@R17] There does, however, appear to be an exaggerated postprandial lipaemic response in individuals with paraplegia compared with able-bodied individuals.[@R18] These observations are of potential concern as the high dietary intake of carbohydrate and fat in individuals with SCI[@R19] may lead to repeated exaggerated elevations in glucose and lipids following food intake. It is thus pertinent to identify interventions to reduce postprandial glucose and lipid responses in individuals with SCI to reduce their CVD risk.

Physical activity guidelines have been developed specifically for the SCI population that recommend engaging in at least 30 min of moderate-to-vigorous physical activity (MVPA) three times per week for CVD health benefits.[@R20] However, it is estimated that 37%--50% of this population engage in no leisure-time physical activity whatsoever.[@R21] Reduced levels of physical activity are proposed to largely account for the increased CVD risk in SCI with reduced levels of leisure-time physical activity associated with increased body fat, insulin resistance and systolic blood pressure.[@R22] However, sedentary behaviour (ie, any waking behaviour in a sitting, reclining or lying posture with low energy expenditure)[@R24] is now recognised as being a significant CVD risk factor in the able-bodied population, independent of MVPA.[@R25] Experimental studies in able-bodied individuals have reported an acute reduction in postprandial glucose, insulin, triglycerides and blood pressure in response to breaking up prolonged sedentary time with 2 min bouts of light or moderate-intensity walking every 20 min.[@R26] However, no research has examined whether postprandial CVD risk marker responses are attenuated in response to breaking up prolonged sedentary time in individuals with SCI.

The primary aim of this study is therefore to compare the acute CVD risk marker responses in individuals with SCI to (1) breaking up prolonged sedentary time, with (2) uninterrupted sedentary time. The CVD risk markers that will be studied include postprandial glucose (primary outcome), insulin and lipids, and systolic and diastolic blood pressures (secondary outcomes) based on evidence that these markers predict CVD outcomes and are adversely affected by SCI. It is hypothesised that breaking up prolonged sedentary time will result in favourable CVD risk marker responses compared with uninterrupted sedentary time in individuals with paraplegia. This could identify a novel strategy for the prevention of CVD in SCI that would warrant further evaluation.

Methods and analysis {#s2}
====================

Study design {#s2a}
------------

A randomised two-condition crossover design will be used in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement.[@R30] The study schedule can be seen in [figure 1](#F1){ref-type="fig"}. All research will take place at the University of Bedfordshire Sport and Exercise Science Laboratories. After preliminary measures, participants will complete two experimental conditions in a randomised order. The conditions will be separated by ≥6 days to eliminate any potential carry-over effects. Condition order will be randomised by a researcher independent from the study using computer-generated random numbers (block randomisation with balanced block sizes).

![Study schedule.](bmjopen-2018-021936f01){#F1}

Participants {#s2b}
------------

### Inclusion criteria {#s2b1}

Males and females aged 18--60 years; chronic SCI (≥1 year since injury), individuals with a traumatic SCI below T5 (mid to low level paraplegia), individuals with a non-traumatic SCI (as defined by the International Spinal Cord Injury Data Sets for non-traumatic SCI[@R31]) that present with mid to low level paraplegia. Including only individuals with injuries below T5 will ensure sympathetic innervation to the major organs at the T5 level so that heart rate and catecholamine responses would be unaffected by injury[@R32] and thus minimise the potential that innervation variations could have on the study outcomes. Individuals with paraplegia who have complete or incomplete lesions will be included based on evidence that these groups do not differ with respect to postprandial glucose metabolism (primary outcome).[@R15] Individuals who express an interest in taking part in the study will be required to indicate their spinal cord lesion level and completeness of injury via a questionnaire and asked to provide the research team with a copy of medical records to confirm injury level and American Spinal Injury Association (ASIA) impairment scale classification prior to preliminary measures.

### Exclusion criteria {#s2b2}

Individuals who regularly engage in \>300 min/week of MVPA as such high levels of physical activity may offset the detrimental association of sedentary time with health outcomes[@R33]; history of severe cardiovascular complications; hypotension (resting blood pressure \<90/60 mm Hg); body mass index \>45 kg/m^2^; a history of autonomic dysreflexia; pregnancy; taking glucose-lowering medication; smokers; diagnosed diabetes, renal failure, liver disease, major illness or other health issues that may limit the ability to perform the physical activity protocols.

Recruitment {#s2c}
-----------

Participants will be recruited through organisations and charities relevant to individuals with SCI, including the National Spinal Injuries Centre, Stoke Mandeville Hospital, Buckinghamshire NHS Healthcare Trust; local sport and activity clubs; and local community groups. Mail outs, social media, information on websites, posters, flyers and visits from the research team will be used to provide information on the study to potentially eligible individuals who can then express their interest to the research team in taking part in the study. Written informed consent will be obtained by a member of the research team prior to participation in any testing protocols (see online [supplementary file](#SP1){ref-type="supplementary-material"}). As an incentive, participants will receive a £25 shopping gift voucher for each main condition they complete and will have all travel expenses paid.
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Preliminary measures {#s2d}
--------------------

Participants will attend a preliminary testing session where they will have body mass measured using wheelchair double beam scales (300 series; Marsden, London, UK). They will also have body fat and lean tissue mass (and per cent) determined for the whole body and regionally via whole-body scans using dual-energy X-ray absorptiometry (DXA; GE Medical Systems; Chalfont St Giles, UK) in line with previous research.[@R34] During DXA measures, participants will be positioned as closely as possible to standard protocols, and Velcro restraints will be fastened around the participants' knees and ankles to maintain correct position of the legs during scanning. Participants will be offered a wedge to be used as a pillow for comfort. Waist circumference will be measured using the International Society for the Advancement of Kinanthropometry (ISAK) International Standards for Anthropometric Assessment guidelines.[@R37] These measures will be taken in the standing position for participants who are able to maintain this posture and in a supine position for participants who are not able to stand.[@R38] Resting blood pressure will be measured on the left arm, while seated, three times after the participant has rested for 5 min with the lowest readings being recorded. Following this, participants will be familiarised with use of the Borg 6--20 Rating of Perceived Exertion (RPE) scale.[@R39] They will then cycle using an arm ergometer (Lode Angio; Lode, Netherlands) to determine the intensity (power output) that yields an RPE of 13 (somewhat hard) in line with previous sedentary behaviour research.[@R26] Participants will be asked to cycle at \~70 rpm during the test. The test will start at a low intensity (\~20 Watts) and the participants will then indicate their RPE at 1 min intervals. The resistance will then be increased by 5--20 Watts based on the participants' RPE until an RPE of 13 has been achieved, at which point the test will be terminated. The test is expected to take no longer than 15 min. The intensity that corresponds to an RPE of 13 during the test will be recorded for each participant and used for the physical activity breaks described in the respective main condition below. The use of the Borg 6--20 RPE scale has acceptable validity in individuals with SCI to determine physical activity intensity.[@R41] This method is also suggested as a practical approach for healthcare professionals and scientists as oxygen consumption testing equipment is costly and not available in many rehabilitation centres and community settings.[@R41]

Experimental protocol {#s2e}
---------------------

[Figure 2](#F2){ref-type="fig"} shows the experimental protocol. Participants will be instructed to refrain from caffeine, alcohol and exercise for 48 hours prior to each experimental condition. They will also be provided with a food diary and digital weighing scales to record volume and timings of all food and liquids consumed in the 24-hour period prior to the first experimental condition. Participants will be asked to replicate their diet the day prior to the subsequent experimental condition.[@R42] On condition days, participants will attend in the morning following an overnight fast and avoid active travel to the laboratory. On arrival, resting blood pressure will be measured after 5 min rest; two measures will be taken and the lowest of these recorded. A fasting capillary blood sample will then be collected. Participants will commence the 5½-hour condition period following consumption of a standardised breakfast. The two experimental conditions are as follows:*Uninterrupted sedentary time (SED)*: participants will remain seated and inactive in their wheelchair or a standard chair at a desk during this condition.*Sedentary time interrupted with physical activity breaks (SED-ACT)*: participants will complete 2 min of moderate-intensity arm-crank activity every 20 min at \~70 rpm using the Lode Angio arm ergometer. These 15 breaks will equate to a total of 30 min physical activity.

![Schematic of experimental protocol.](bmjopen-2018-021936f02){#F2}

The SED-ACT protocol was selected based on previous research that reported a significant reduction in 5-hour postprandial glucose in response to breaking up prolonged sitting time with 2 min light-intensity walking every 20 min versus uninterrupted sitting in able-bodied participants.[@R28] An RPE of 13 for the physical activity intensity was selected in line with previous research,[@R26] and the Borg 6--20 RPE scale may be used to assess and regulate upper-body physical activity at moderate-to-vigorous intensity in adults with chronic SCI.[@R41] Moderate-intensity physical activity was selected as it is well tolerated, can be performed safely and is recommended for health risk reduction in individuals with SCI.[@R20]

Participants will be permitted to work on a laptop computer, read, talk or watch DVDs during each condition. This will be standardised by asking participants to engage in the same activities during each of the two experimental conditions. Except during the activity bouts, participants will remain inactive and only leave their desk to void and consume standardised meals in a kitchen adjacent to the test laboratory; participants will be aided by a member of the research team when moving to these locations so that they remain inactive. A researcher will be present to ensure compliance with the protocols throughout all conditions.

Meal and water consumption {#s2f}
--------------------------

Standardised meals will be consumed immediately prior to the start of each experimental condition and at 3 hours, each providing 30% of estimated daily energy requirements for each participant.[@R44] Participants will be asked to consume each meal within a 15 min time period. The time taken to consume the meals will be recorded for the first condition, and participants will be asked to replicate this time as closely as possible in the subsequent condition. Breakfast will consist of bran flakes, whole milk, croissant, butter and orange juice (54% carbohydrate, 34% fat, 12% protein) and lunch will be a chicken sandwich, salted crisps and apple (54% carbohydrate, 34% fat, 12% protein). The macronutrient composition of meals in the current study has been selected as it is generally representative of UK guidelines for a balanced diet.[@R45] The glycaemic index for these breakfast and lunch meals is 43 and 72, respectively. Glycaemic index values for each food item were obtained from the International Tables of Glycaemic Index and Glycaemic Load Values 2008,[@R46] and meal glycaemic index was calculated using weighted means of the glycaemic index values for the component foods.[@R47] Water will be available ad libitum during the first condition, and this volume of intake will be provided at standardised regular intervals in the subsequent condition.

Blood collection and biochemistry {#s2g}
---------------------------------

Finger prick blood samples will be collected into two EDTA-containing microvettes (Microvette CB300 EDTA, Sarstedt, Leicester, UK) at baseline and at 30, 60, 90, 120, 180, 210, 240, 300 and 330 min. Blood samples will be collected before the hourly activity bouts in SED-ACT. At each time point, approximately 600 µL of whole blood will be collected. Blood glucose concentrations will be analysed immediately using the YSI 2300 STAT plus glucose and lactate analyzer (YSI, Yellow Springs, Ohio, USA) from 30 µL of blood from one microvette. Additional 30 µL volumes of whole blood will be aliquoted onto two separate Reflotron test strips (Roche Diagnostics, Burgess Hill, UK) for the measurement of triglyceride and HDL concentrations using the Reflotron Plus system (Roche Diagnostics, Burgess Hill, UK). The remaining whole blood (\~490 µL) will be centrifuged at 2500 x g for 5 min (Heraeus Pico 17, Thermo Scientific, Loughborough, UK) and the plasma then stored at −80°C. An ELISA kit will be used to determine plasma concentrations of insulin (Mercodia, Uppsala, Sweden).

Blood pressure {#s2h}
--------------

Blood pressure will be measured at baseline as described above followed by single readings taken at 60, 120, 180, 240, 300 and 330 min. Readings will be taken 5 min before the hourly activity bouts in SED-ACT. Blood pressure will be measured using an automated oscillatory blood pressure monitor (Omron M5-I; Omron Matsusaka, Matsusaka, Japan).

Study outcomes {#s2i}
--------------

### Primary outcome {#s2i1}

The primary outcome for the study is within-participant, between condition postprandial glucose net incremental AUC (iAUC).[@R11]

### Secondary outcomes {#s2i2}

These include within-participant, between condition mean systolic and diastolic blood pressures, and net iAUC for postprandial triglycerides, HDL and insulin. Positive iAUC and total AUC will also be calculated for postprandial glucose, insulin, triglycerides and HDL to permit comparisons with previous studies.

### Feasibility measures {#s2i3}

To assess feasibility of the trial, participant dropout, number of experimental sessions completed, fatigue at the beginning and end of each day rated on an 11-point (0 'not fatigued at all' to 10 'extremely fatigued') Visual Analogue Scale (VAS) and the degree of difficulty in completing each experimental condition rated on an 11-point VAS (0 'not difficult at all' to 10 'extremely difficult') will be recorded. Participants will also complete the Physical Activity Enjoyment Scale[@R48] at the end of the SED-ACT condition and report their enjoyment on a 200 mm VAS[@R49] ('Enjoyment') 20 min after the last activity bout in the SED-ACT condition. Participants will also report on the same scale how enjoyable they would find it to engage in this form of physical activity most days of the week in the coming month ('Expected enjoyment').

### Psychological outcomes {#s2i4}

Correlates of sedentary behaviour will be measured immediately before and after each experimental condition to explore whether participants' mood, affect, well-being and social cognitions regarding their ability to overcome being sedentary may differ in response to the SED-ACT condition compared with the SED condition. These measures will be based on the Theory of Planned Behaviour[@R50] using standardised wording formats[@R51] that will include overcoming barriers (self-efficacy/perceived behavioural control), attitudes, intentions and action planning. The following questionnaires will be completed in this order: psychological well-being using the National Well-being Measurement[@R52]; the Warwick Edinburgh Mental Well-Being Scale[@R53]; current mood using the short Positive and Negative Affect Scale[@R54]; and an adapted version of the Schwarzer and Renner[@R55] Physical Exercise Self-Efficacy Scale to measure self-efficacy to avoid long periods of sedentary time. These measures will be taken at the end of each experimental condition (330 min) meaning that each questionnaire will be completed within 45 min following the last bout of activity in the SED-ACT condition. This is an appropriate time frame based on evidence that mood and affect are enhanced for 3--4 hours following a single session of exercise.[@R56] Although between-participant variation in the time taken to complete each questionnaire is anticipated, within-participant variation is expected to be limited, therefore permitting valid between-condition comparisons.

Sample size calculations {#s2j}
------------------------

Sample size calculations were performed using GPower.[@R57] Previous research reported a 16% reduction (effect size, *F*=0.61) in 5-hour postprandial glucose total AUC when breaking up prolonged sedentary time with 2 min light-intensity walking every 20 min versus uninterrupted sitting in able-bodied participants.[@R28] As this study will use arm cranking (localised muscular contractions) as opposed to walking where a larger muscle mass is required, a smaller effect may be observed. Based on this, it was estimated that 12 participants would be required for this complete two-treatment crossover design to detect a medium effect size (*F*=0.4) with a within-person correlation of 0.6, 80% power, and an α of 0.05. To allow for potential withdrawals, a total of 18participants will be recruited.

Statistical analysis {#s2k}
--------------------

Linear mixed models will be used to determine differences in the primary and secondary outcome variables between the conditions. All models will adjust for potential covariates explaining residual outcome variances (age, body fat%, gender, lesion level, completeness of lesion and preprandial outcome values). Statistical significance will be accepted as p≤0.05. Cohen's d effect sizes will be calculated to describe the magnitude of differences between conditions.[@R58] Individuals' responses for CVD risk marker outcomes will also be compared between the conditions to determine the number of participants who respond to the experimental protocols.

Patient and public involvement {#s2l}
------------------------------

Patients and public were not involved with the development of the research question, outcome measures or study design, nor will they be involved with the conduct of the study. The recruitment plan was informed based on feedback from patients and public. A summary of the study results will be provided to each of the study participants.

Ethics and dissemination {#s2m}
------------------------

Personal information about potential and enrolled participants will be stored in electronic format on password-protected computers or in hard copy format in locked filing cabinets at the University of Bedfordshire. Only members of the research team will have access to this information. All personal information will be destroyed after a period of 5 years. Individuals will be referred to in anonymised fashion in any published data.

The findings of this research will be disseminated to lay, academic, practice and policy-based audience via presentation at conference proceedings; publication in a peer-reviewed journal; websites, newsletters and social media; and summary reports to policy-makers and clinical care partners. The final trial dataset will be made available as supplementary material when the findings of the study are published in a peer-reviewed journal. Any protocol modifications will be communicated to the Cambridge South National Health Services Research Ethics Committee, recorded in the study's ISRCTN clinical trials registry and detailed in a journal publication of the study findings.
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